Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology. Baxter has paid US$25 M upfront to advance Chatham’s haemophilia B programme through early clinical trials and has global marketing and commercialisation rights to resulting therapies.